{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(Suppl 6)"],"submitter":["Lukas R"],"pubmed_abstract":["Abstract <h4>BACKGROUND</h4> IDHwt glioblastoma with unmethylated MGMT gene promoter carries a poor prognosis. Preclinical studies have shown that combination of radiotherapy and dual immunotherapy with nivolumab and IDO inhibition significantly prolongs survival of mice with an orthotopic glioblastoma [Ladomersky, et al. CCR 2018;24(11):2559-2573]. In a clinical trial in patients with newly diagnosed glioblastoma with unmethylated MGMT we substituted temozolomide for dual immunotherapy combination. <h4>METHODS</h4> Phase 1 trial [NCT04047706] using a 3 + 3 dose-escalation design. All received standard radiotherapy (30 x 2 Gy) with addition of once daily oral BMS-986205 and intravenous nivolumab (240mg every 2 weeks) begining on day 1 of radiotherapy and continuing until disease progressio"],"journal":["Neuro-oncology"],"pagination":["vi51-vi52"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8598682"],"repository":["biostudies-literature"],"pubmed_title":["CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA"],"pmcid":["PMC8598682"],"pubmed_authors":["Gondi V","Kumthekar P","Wainwright D","Lesniak M","Lukas R","Sachdev S","Dixit K","James D","Stupp R","Grimm S","Lezon R","Sharp L"],"additional_accession":[]},"is_claimable":false,"name":"CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA","description":"Abstract <h4>BACKGROUND</h4> IDHwt glioblastoma with unmethylated MGMT gene promoter carries a poor prognosis. Preclinical studies have shown that combination of radiotherapy and dual immunotherapy with nivolumab and IDO inhibition significantly prolongs survival of mice with an orthotopic glioblastoma [Ladomersky, et al. CCR 2018;24(11):2559-2573]. In a clinical trial in patients with newly diagnosed glioblastoma with unmethylated MGMT we substituted temozolomide for dual immunotherapy combination. <h4>METHODS</h4> Phase 1 trial [NCT04047706] using a 3 + 3 dose-escalation design. All received standard radiotherapy (30 x 2 Gy) with addition of once daily oral BMS-986205 and intravenous nivolumab (240mg every 2 weeks) begining on day 1 of radiotherapy and continuing until disease progressio","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-05-29T16:11:27.524Z","creation":"2025-04-06T01:50:30.446Z"},"accession":"S-EPMC8598682","cross_references":{}}